ENZ - Enzo Biochem, Inc.
| Previous Close | 2.6800 |
| Open | 2.6800 |
| Bid | 2.7200 x 800 |
| Ask | 3.2500 x 800 |
| Day's Range | 2.6800 - 2.7900 |
| 52 Week Range | 2.3200 - 4.4600 |
| Volume | 126,771 |
| Avg. Volume | 80,155 |
| Market Cap | 133.57M |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | 54.60 |
| EPS (TTM) | 0.0500 |
| Earnings Date | Dec 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Business Wire
Enzo Biochem Issues Open Letter to Shareholders
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today issued an open letter to shareholders. Full text below:
- Business Wire
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2020 Results Tuesday, December 10, 2019 At 4:30 PM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.
- Simply Wall St.
What Kind Of Shareholders Own Enzo Biochem, Inc. (NYSE:ENZ)?
Every investor in Enzo Biochem, Inc. (NYSE:ENZ) should be aware of the most powerful shareholder groups. Institutions...
- Thomson Reuters StreetEvents
Edited Transcript of ENZ earnings conference call or presentation 15-Oct-19 8:30pm GMT
Q4 2019 Enzo Biochem Inc Earnings Call
- Business Wire
Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results
Company’s Vertically Integrated Life Sciences and Labs Business Generates Breakthrough Diagnostic Testing Approvals and Services in Rapidly Expanding Markets
- Business Wire
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal Year 2019 Results Tuesday, October 15, 2019 at 4:30 PM E.T.
Enzo Biochem, Inc. (ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.
- Simply Wall St.
Does Enzo Biochem, Inc.'s (NYSE:ENZ) CEO Salary Reflect Performance?
Elazar Rabbani became the CEO of Enzo Biochem, Inc. (NYSE:ENZ) in 1976. This report will, first, examine the CEO...
- Simply Wall St.
Investors Who Bought Enzo Biochem (NYSE:ENZ) Shares Five Years Ago Are Now Down 41%
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...
- Simply Wall St.
Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- Simply Wall St.
Is Enzo Biochem, Inc.'s (NYSE:ENZ) 2.3% ROE Worse Than Average?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Thomson Reuters StreetEvents
Edited Transcript of ENZ earnings conference call or presentation 11-Jun-19 12:30pm GMT
Q3 2019 Enzo Biochem Inc Earnings Call
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Enzo Biochem, Inc. (NYSE:ENZ)?
If you're interested in Enzo Biochem, Inc. (NYSE:ENZ), then you might want to consider its beta (a measure of share...
- ACCESSWIRE
Enzo Biochem, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on June 11, 2019 at 8:30 AM Eastern ...
- Business Wire
Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
Company Outlines Three-Pronged Short-Term Value Creation and Growth Strategy
- Business Wire
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2019 Results Tuesday, June 11, 2019 at 8:30 AM E.T.
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 25, 2019.
- Business Wire
Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
Enzo Biochem, Inc. (ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod. Ozanimod is a product of Celgene Corporation (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. It targets a different part of the same cell signaling pathway, the “sphingosine pathway,” also targeted by Enzo’s proprietary sphingosine kinase inhibitor, SK1-I, which Enzo is currently developing for the treatment of HCC.
- MoneyShow
Biotech Bets and a Goodbye from a Favorite Expert
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
- Simply Wall St.
What Percentage Of Enzo Biochem, Inc. (NYSE:ENZ) Shares Do Insiders Own?
A look at the shareholders of Enzo Biochem, Inc. (NYSE:ENZ) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the small...
- Thomson Reuters StreetEvents
Edited Transcript of ENZ earnings conference call or presentation 12-Mar-19 12:30pm GMT
Q2 2019 Enzo Biochem Inc Earnings Call
- Associated Press
Enzo Biochem: Fiscal 2Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 18 cents. The life sciences and biotechnology company posted revenue of $19.3 million in the period. In the final minutes of trading ...
- Business Wire
Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals
Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
